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PSTEIN-BARR VIRUS (EBV), a ubiquitous herpes vi-
rus in the human population, naturally infects two host cells, namely, epithelial cells in the oropharynx and B cells.',' Pharyngeal epithelial cells allow viral replication and provide a source for infectious virus, whereas B cells are latently infected.'.' Occasionally, EBV can cause infectious mononucleosis (IM) and, in conjunction with severe immunodeficiency, B-cell lymphoproliferative di~orders.~ The virus has also been linked to endemic Burkitt's lymphoma, nasopharyngeal carcinoma,4' Hodgkin's disease:' gastric carcin o~n a ,~.~ smooth muscle tumors in immune compromised and lymphoproliferative disorder of T cell^'^"^ and natural killer (NK) cells." In vitro, follicular dendritic cellsI6 and endothelial cellsI7 have also been infected with EBV.
Studies of EBV-host interactions have shown different patterns of EBV gene expression and regulation.18-'I Lymphoblastoid cell lines (LCL) derived from EBV immortalization of normal B cells, LCL-like Burkitt's lymphoma cell lines, and peripheral blood B cells from patients with acute EBV-induced IM constitutively express nine EBV latent proteins, namely the nuclear antigens EBNA-1, -2, -3A, -3B, -3C, and -LP, and the latent membrane proteins LMP-1, -2A, and -2B.1.'s-'1 This pattern of EBV gene expression is usually referred to as latency 111. In contrast, Burkitt's lymphoma tissues, early passage Burkitt's lymphoma cell lines, and peripheral blood from EBV-seropositive normal individuals express EBNA-l and LMP-2A, a virus latency pattern referred to as latency
In addition, nasopharyngeal carcinoma, EBV-positive T-cell lymphomas and Hodgkin's disease tissues express EBNA-1, LMP-1, and LMP-2, a virus latency pattern designated as latency II.18-'' The different forms of EBV latency have been linked to differences in promoter usage, and are believed to reflect strategies that the virus uses to invade and/or survive in the human h~s t .~~~'~ Expression of the full array of EBNA and LMP genes, particularly of the growth-promoting LMP-l gene, may reflect the need of EBV to rapidly colonize the host by driving the proliferation of virally infected B ~e l l s . ' '~~~ By contrast, limited expression of EBV genes, namely of EBNA-1 and of LMP-2A proteins that are devoid of growth-transforming properties per se, may reflect a strategy for virus survival in a resting B cell, mostly avoiding immune re cognition."^" streptavidin-PE were also obtained from Becton Dickinson. Biotinylated MoAbs against CD45RA and CD45RO were purchased from Pharmingen (San Diego, CA) and Dako (Carpenteria, CA), respectively.
The MoAbs anti-Tac (anti-interleukin [IL]-2Ra, mouse immunoglobulin G2a [IgG2a])*' and MikPl (anti-IL-2RP, mouse IgG2a)3" were kind gifts from Dr T.A. Waldmann (National Institutes of Health, Bethesda, MD); TUGh4 (anti-IL-2Gy, rat IgGZb)" was a kind gift from Dr K. Sugamura (Tohoku University, Sendai, Japan); and the anti-early antigen-diffuse component (EA-D) MoAb R3 (mouse IgG1) was a kind gift of Dr G. Pearson (Georgetown University, Washington, DC)." PE-conjugated goat antimouse Ig and antirat Ig were obtained from Southern Biotechnology Associates (Birmingham, AL). FITC-conjugated goat antimouse IgG antibody was obtained from Cappel, Organon Technical (Durham, NC). Immunofluorescence was performed by direct or indirect methods, and the stained cells were analyzed using FACScan flow cytometer equipped with a Cell Quest data analysis program (Becton Dickinson), as described p r e v i o~s l y .~~ For analysis of EA-D expression, fluorescence microscopy was used.
Imrnunoblotting. Cells were washed twice in phosphate-buffered saline (PBS), and cell pellets were lysed in electrophoresis sample buffer and boiled for 10 minutes. The equivalent of 2 X IO5 cells was loaded into each lane of 8% Tris-glycine gels (Novex, San Diego, CA). The electrophoresed proteins were transferred onto nitrocellulose membranes (Immobilon-P; Millipore, Bedford, MA). Blots were washed twice in PBS with 0.05% Tween 20 (PBS-T), blocked in 5% skim milk in PBS overnight, and incubated with human serum with high titer antibodies against EBNAs, with a MoAb directed against LMP-I (S12, mouse IgG2a)," with a pool of MoAbs directed against LMP-l (CS1-4, mouse IgG135 from Dako), or with a MoAb directed against EBNA-2 (PE2, mouse IgGl)" in PBS-T at room temperature for 1 hour. After rinsing four times in PBS-T for 5 minutes, blots were incubated for 1 hour either with horseradish peroxidase-conjugated protein A (Bio-Rad Laboratories, Hercules, CA) for detection of bound antibody in human serum and in the S12 (anti-LMP-l) MoAb, or with horseradish peroxidase-conjugated goat antimouse IgGl (Southern Biotechnology Associates) for detection of bound CS1-4 (anti-LMP-l) MoAb and bound EBNA-2-specific MoAb. Immunoblots were rinsed five times for 10 minutes in PBS-T, and then developed by using the ECL Western blotting detection systems (Amersham Life Science, Arlington Heights, IL). Prestained molecular weight markers (rainbow-colored protein) were obtained from Amersham.
DNA preparation and polymerase chain reaction for EBV DNA. Cells were washed twice in PBS and cellular DNA was extracted with phenol and chloroform, precipitated with ethanol, and resuspended in distilled water. A 0.1-pg quantity of each sample was used for one-step typing of EBV by polymerase chain reaction (PCR) amplification as described elsewhere." The oligonucleotide sequences for amplification of the EBV U2 region were 5"TTTCAC-CAATACATGAACC-3' (277 1-2789) and 5"TGGCAAAGTGCT-GAAAGCAA-3' (3149-3 130). An amplification was performed in 50 p L containing 20 mmolL Tris-HCI (pH 8.4), 50 mmol/L KCI, I .5 mmol/L MgC12, 0.2 mmol/L dNTP mixture, 0.4 pmolk of each primer, and 2.5 U of Tay DNA polymerase (GIBCO BRL). An initial denaturation step of 3 minutes at 95°C was followed by 35 cycles of denaturation at 95°C for 1 minute, annealing at 57°C for I minute, and extension at 73°C for 2 minutes followed by a final extension step of 7 minutes at 73°C on a RoboCycler (Stratagene, La Jolla, CA). Each amplified product was electrophoresed through a 2% agarose gel prestained with 1 pg/mL of ethidium bromide, and was visualized under UV light. Expected lengths of the amplified products derived from type 1 and type 2 EBV were 378 bp and 483 bp, respectively.
RNA preparation and reverse transcriptase PCR for EBV receptor and EBV latent genes.
Total RNA was extracted from the cell pellets using the guanidinium thiocyanate-phenol (RNAzol; Cinn/ Biotex, Friendswood, TX) method. The first cDNA strand was synthesized from 5 pg of total RNA using the Superscript preamplitication system (GIBCO BRL). The reaction mixtures containing either CR2 (EBV receptor)-specific primers (500 pmol) with random hexamer primers (0.5 pg) for CR2 transcripts or specific primers for EBV latent genes with oligo (dT)12.,8 (0.5 pg) were incubated for 50 minutes at 42°C. The sequence of the CR2-specific primer that hybridizes across the junction of exon 12a and 12b is 5"AACTGG-TACCCATCT-3'.'' PCR amplifications were performed in 50 pL of the reaction mixture described above containing 5 pL of firststrand cDNA. For the detection of CR2 transcripts within exon 8b, the sequences of the primer pair were 5'-AATGCAAAGTGGCAG-CGTGTGAAG-3' (across the junction of exon 7 and 8a) and 5'-ACACTTGAATGTCACAGTGTCATT-3' (exon 9, IO). After an initial denaturation at 94°C for 10 minutes, Taq DNA polymerase was added to the reaction mixture followed by 40 cycles of denaturation at 94°C for 45 seconds, annealing at 57°C for 30 seconds, and extension at 72°C for 90 seconds followed by a final extension of 7 minutes at 72°C. Expected lengths of the amplified products are either 420 or 497 bp, depending on the presence or absence of the short consensus repeat 8b. For the detection of EBV latent genes, 5 pL of cDNA was used as a template for the first PCR application. Table 1 ),2a.3' and 2.5 U of Taq DNA polymerase. The samples were subjected to 25 to 35 cycles of amplification for the outer primers. For the nested PCR, 0.5 to 2 pL of the first amplified product was used as a template for 30 to 35 cycles of amplification within the inner primers. An initial denaturation of 95°C for 3 minutes was followed by 25 to 35 cycles of denaturation at 95°C for 30 seconds, annealing at 51 to 67°C (depending on the primers used) for 1 minute, and extension at 72°C for 2 minutes, followed by a final extension of 72°C for 7 minutes. The amplified products were subjected to electrophoresis through 2% agarose gels prestained by ethidium bromide, and were visualized under UV light.
EBV in situ hybridization. The procedure was performed by using the EBV Polyprobe Kit (Novocastra Laboratories, Newcastle upon Tyne, UK). Briefly, YTNlO cells and control cells were cytocentrifuged on 3-aminopropyltriethoxy-silane-coated glass slides, air-dried, and fixed in 10% buffered formalin solution. After rinsing and dehydration, hybridization was performed using an FITC-conjugated EBV probe specific for EBV-encoded small RNA (EBER). After hybridization for 2 hours at 3 7 T , the slides were washed, incubated for 30 minutes at room temperature with alkaline phosphatase-conjugated rabbit F(ab') anti-FITC antibody, and then developed using 5-bromo-4-chloro-3-indolyI phosphate and nitro blue tetrazolium.
Gardrlla gel ana1ysi.s for episomal and linear EBV DNA. Episome (circular) DNA in cells was analyzed by Gardella gel electrophoresis.'" A quantity of 2 X 10' cells were suspended in 0.1 mL of sample buffer (15% Ficoll, 0.1% bromophenol blue, and 100 pg/ mL RNAase in 89 mmol/L Tris-borate buffer, pH 8.0), were loaded on a vertical, 0.75% agarose gels with an agarose plug containing 1 % sodium dodecyl sulfated (SDS) and 1 mg/mL pronase. The electrophoresis ran at 10 V for 4 hours and then 100 V for 18 hours. The DNA separated through the gel was partially depurinated with 0.25 molL HCI, denatured in 0.5 mol/L NaCl in 1.5 moln NaCI, neutralized, and transferred to a nylon filter. The filter was then hybridized to an EBV BamHI W DNA fragment labeled with "P by random priming. The filter was washed with 0.1 X saline sodium For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From citrate (SSC), 1% SDS, and exposed to Kodak XAR film (Eastman Kodak, Rochester, NY) at -70°C.
RESULTS
The cell-surface phenotype of YTNlO cells was analyzed to confirm that they had maintained their originally described NK phen0type,2'.'~ and to determine if they expressed any cell marker typical of EBV infe~tion.'.~ YTNlO cells expressed the NK-cell-specific surface determinant CD56, as well as HLA-DR antigens, but did not express the other NKcell-associated marker CD16 antigen or the mature T-cellassociated marker, CD3 antigen (Fig 1) .27,28 Whereas the original YT cells expressed CD25, the IL-2Ra chain,27 the YTNlO subclone did not express this antigen. As previously reported for the parental YT cells and characteristic for NK cells:' YTNlO cells expressed the IL-2RP and y chains at high levels. The CD45RO antigen was also highly expressed on YTNlO cells, but the CD45RA antigen was only weakly expressed. Although it was reported that the B-cell-associated markers CD20, CD21, and CD23 antigens were absent on YT cells,28 we found them to be expressed at very low levels on YTNlO cells. Thus, YTNlO cells belong to the NKcell lineage, as they express surface markers characteristic of NK cells, and fail to express or express at very low levels T-cell-and B-cell-associated markers.
The CD21 antigen is the EBV receptor on B lymphocytes:* and CD21 transcripts are present in epithelial cells that can also be infected with EBV.2,3,38 We looked for EBV receptor transcripts by reverse transcriptase (RT)-PCR analysis (Fig 2) . The expected 497-bp band was detected in the sample from the lymphoblastoid VDS-0 cell line. In addition, a faint 497-bp band was reproducibly derived from YTNlO cells (Fig 2) . These results indicated that YTNlO cells express the CD21 gene, and suggest that EBV may utilize a common cell-surface receptor to infect B cells, epithelial cells, and NK cells.
In situ hybridization using probes for the highly transcribed EBER showed that greater than 95% of YTNlO cells are EBER-positive, although the signal was weaker than that derived from B95-8 and VDS-0 cells used as positive controls (Fig 3) . The EBV-negative BJAB cells gave negative results. Expression of EBV latent genes in YTNlO cells was first examined by Western blotting. Using a human serum reactive to EBNAs:' YTNlO cells were found to express EBNA-1, but not EBNA-2 (Fig 4A) . Differences in the EBNA-1 molecular weight are common due to viral strain variation of the internal repeat region 3 within the EBNA-1 coding region.' The EBNA-1 in YTNlO cells, approximately 85 Kd, was slightly smaller than the EBNA-l in B95-8, VDS-0, and Ag876 cells (approximately 87 Kd), indicating that the EBV strain infecting YTNlO cells was distinct from those common laboratory strains. EBV earlyantigen expression was also detected in YTNlO cells, indicating that a fraction of the cells were undergoing lytic EBV infection (Fig 4A) .
The absence of EBNA-2 expression in YTNlO cells could not be attributed to infection with a type 2 (or B) EBV strain. Two types of EBV have been classically defined by differences in the U2 region encoding EBNA-2 resulting in distinct serologic rea~tivities.~~ PCR amplification with EBNA-2-specific primers, which distinguish type 1 (or A) and type 2 (or B) EBNA-2, indicated that YTNlO cells are infected with a type 1 (or A) EBV (Fig 5) . As expected, type 1 EBV was detected in B95-8 and VDS-0 cells, whereas type 2 EBV was detected in Ag876 cells (Fig 5) . In addition, immunoblotting with a MoAb directed to a typeindependent epitope of EBNA-236 detected both the EBNA-2A in B95-8 and VDS-0 cells and the EBNA-2B in Ag876 cells, but failed to detect either EBNA-2 protein in YTNlO cells (Fig 4D) .
EBNA-1 expression in the absence of other EBNAs is consistent with a latency I or I1 pattern of viral gene expression that is typically associated with Burkitt's lymphoma tumors, nasopharyngeal carcinomas, and Hodgkin's disIn latency I and 11, EBNA-1 is transcribed from a unique promoter approximately 50 kb downstream of the EBNA promoter used in latency III.** These latency patterns can be distinguished in RT-PCR assays using either primers that specifically identify the latency I/II EBNA-I transcripts originating from a promoter (Qp) in the BurnHI Q region of the viral genome, or primers that identify latency 111 EBNA- 1 transcripts originating from either the BarnHI C promoter (Cp) or the BarnHI W promoter (Wp). As shown in Fig 6, EBNA-I transcripts could be RT-PCR-amplified from all EBV-infected cells, including YTNIO cell using primers in the common EBNA-I BurnHI U and K exons. In contrast, no EBNA-I transcripts were derived from the EBV-negative BJAB cell line. EBNA-l transcripts typical for latency 111 (EBNA-I transcribed from either the Cp or Wp promoter detected with primers localized in the exons BarnHI K and BurnHI Y3) could be derived from B95-8, VDS-0, and Ag876 cells, but not from YTNIO cells (Fig 6) . As expected, a percentage of B95-8 and Ag876 cells also expressed latency VI1 EBNA-I transcripts (EBNA-I transcribed from the Qp promoter detected with primers from the BurnHI Q and BurnHI K exons). EBNA-1 transcripts in YTNlO cells could only be detected with primers from the BurnHI Q and BurnHI K region of the viral genome, consistent with a latency VI1 transcription pattern initiated from the promoter Qp (Fig 6) . EBNA-2 transcripts could not be amplified from YTNIO cells (Fig 6) , consistent with the immunoblotting classifica- (Fig 4B) , and these differences might be due to different sequences in LMP-I carboxy termini. Failure of the S 12 MoAb to detect an LMP-I gene product from YTNlO cells on Western blotting (Fig 4B) may be due either to EBV strain variation in the LMP-1 carboxy terminus where the S 12 epitope is located," or to low-level LMP-I expression not detectable by Western blotting. To examine these possibilities, we used a pool of CS14 MoAbs that recognize epitopes distinct from that recognized by the S12 MoAb."' As shown in Fig 4C, CS14 MoAbs detected an LMP-l protein from YTNIO cells. In addition, immunostaining of YTNIO cells using CSI-4 MoAbs detected 23% cell positivity, whereas the S12 MoAb consistently gave negative results (data not shown). Sensitive antisera for LMP-2 expression are not readily available, so that LMP-2 expression is typically assayed by RT-PCR. LMP-2A specific primers consistently detected a weak but positive LMP-2A transcript in YTNIO cells (Fig 6) . LMP-2A-specific transcripts were also derived from the B95-8, VDS-0, and Ag876 cells, but not from the EBVnegative BJAB cell line. Thus, RT-PCR analysis is typical for latency I1 viral gene expression in YTNlO cells.
CD21 GAPDH
Restricted EBV gene expression could also be due to abnormal integration and disruption of latent gene coding sequence.' Analysis for episomal EBV DNA by in situ lysing gels, as described by Gardella et detected the presence of an EBV episome similar in size to that present in B95-8 and VDS-0 cells, suggesting the presence of an intact EBV genome in Y T N l O cells (Fig 7) . This analysis also indicated a relatively low viral copy number in YTNIO cells. Presence of a faster migrating band in YTNIO cells is consistent with linear viral DNA and viral replication (Fig  7) , as suggested by the immunoblot detection of early antigen lytic cycle gene expression (Fig 4A) . In addition, immunofluorescence analysis of Y T N l O cells using the anti-early antigen MoAb R3 detected a few (0.2%) clearly positive cells (data not shown).
DISCUSSION
EBV has developed a successful strategy for infection, spreading, and persistence in humans"' that uses a dynamic range of viral gene expression. Key features to the successful penetration of EBV in humans are the intermittent viral replication in the pharyngeal epithelium that ensures spread to new hosts, and the establishment of a lifelong latency in B cells that ensures viral persistence.' B lymphocytes appear central to EBV persistence in humans. During initial EBV infection associated with IM, a relatively large pool of latently infected B cells is Recently, it was reported that the spectrum of viral RNAs expressed in these cells is broad, including all six nuclear antigens (EBNA-1, -2, -3A, -3B, -3C, -LP) and the membrane proteins (LMP-I 1 and -2A).I9 This pattern is comparable to that found in Blymphocyte growth immortalized by EBV in vitro, and was interpreted to reflect the need of EBV to rapidly colonize the host, before the development of specific immunity.'.'x.'Y Once the host-cell-mediated responses develop, the pool of EBV-infected B cells in the circulation is substantially reduced, and is believed to reside in nonproliferating cells.'"" It was reported that the spectrum of viral RNAs expressed in these cells is limited to EBNA-l and LMP-2A, viral products not known to have growth-transforming ability.".2" This more restricted form of latent EBV gene expression may reflect the need of EBV to persist in the host avoiding destruction by cytotoxic T ceIls. 4' EBV latent gene expression is equally diverse in various EBV-associated malignancies. EBV-positive Burkitt's lymphomas generally express only EBNA-I and low levels of LMP-2A. a pattern believed to be shared by most latently infected normal peripheral blood B cells in seropositive norm a l~. '~-'~ However, unlike these normal, phenotypically resting cells, Burkitt's cells are cycling and rapidly expanding. It was suggested that this proliferative state is not driven by EBV, but by the constitutive expression of c-myc secondary to its translocation.In Thus, EBV would be maintained in the dividing tumor cells by virtue of EBNA-I expression, but would not play a major role in the expansion of the malignant cells. In contrast, most EBV-infected B cells in posttransplant lymphoproliferative disease typically express the latency Ill program, which probably reflects the direct dependence of these tumors on the growth-promoting effects of the EBV latent genes.I8'*' Yet another pattern of EBV latency was described in EBV-positive nasopharyngeal carcinomas, Hodgkin's disease, and T-cell lymphomas." Here EBNA-l is expressed in the absence of other nuclear proteins along with variable amounts of LMP-I and -2 ranging from trace levels to high level^?^^'^^'^ This pattern of EBV latency, recently described also in epithelial cells infected with EBV,45 may represent a compromise by the virus to fulfill at the same time both a need to promote growth and to limit immune recognition.
Despite the fact that EBV-associated lymphoproliferative diseases with an NK-like phenotype are reported with in- creasing frequency, little is presently known about virus-cell interactions in these In addition, lymphoproliferative diseases involving EBV-infected NK cells include acute and rapidly fatal leukemias, nodal and extranodal lymphomas. progressive lymphoproliferative disorders, and, occasionally, chronic benign expansions of NK cells.'5~'J-'h It is conceivable that virus-cell interactions might differ in the various disorders, and that these differences might underscore different roles that the virus plays in the disease pathogenesis.
In the present studies, we have shown that the NK-like YTNlO EBV-positive cell line derived from a patient with the diagnosis of lymphoblastic lymphoma is infected with type I EBV, contains both episomal and linear DNA, expresses EBV receptor molecules albeit at low levels, and exhibits a type I1 virus latency program characterized by expression of EBNA-I in the absence of other nuclear proteins, accompanied by low level expression of LMP-I and LMP-2A. As described here, this latency pattern is observed in the majority of nasopharyngeal carcinomas. Hodgkin's disease, and T-cell lymphomas,'X and contrasts with the latency 111 pattern typically observed in EBV-positive B cells in posttransplant lymphoproliferative diseases. The distinction between latency I and I1 can be somewhat arbitrary, because the presence of weak LMP transcripts may be due to a fraction of latency I cells making a transition to latency 11, as shown by certain Burkitt's tumor cell lines grown in tissue culture." However, in contrast to these Burkitt's tumor cell lines cultured in vitro, the latency I1 pattern in YTNlO cells is noticeable for its stability and complete lack of latency 111 expression over time. Thus, the EBV latency in this lymphocytic cell line of NK lineage is more reminiscent of the tight latency I1 pattern in epithelial cells" and Hodgkin's
The ability of YTNlO cells to proliferate in the absence of growth-promoting latency 111 EBV gene expression suggests that EBV infection is not likely to be the sole reason for their immortalized state. Although the transforminghmmortalizing event(s) remain undefined, the observation that YTN I O cells have an abnormal karyotype, namely are tetraploid and exhibit a 4+ duplication, is consistent with the possibility that the cells have incurred some genetic damage in addition to EBV infection. EBV was found to be monoclonal on early passage YT cells," suggesting that EBV infection preceded and possibly contributed to the malignant transforming event, similar to the viral pathogenesis implicated in Burkitt's lymphoma and nasopharyngeal carcinoma. For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From indicate the occurrence of virus production."3 Previous studies have identified a distinct in vitro pathway of direct entry of cells with lytic virus cycle without associated broadening of the pattern of latent nuclear antigens expression. 46 When activated with anti-Ig, Akata cells were found to continue expression of EBNA-1 from the Qp promoter, and to rapidly begin expression of LMP-1, -2A, and -2B together with early lytic cycle antigens. 46 This pattern of gene expression is very similar to the pattern observed in YTNlO cells. Activation from latency VI1 directly into the cell cycle would represent a mechanism to avoid T-cell immunosurveillance. In addition, latency I/II cells could provide a reservoir for virus persistence and virus production.
The presence of EBV in malignant cells might be considered in the design of strategies for these disorders. We know that immunocompetent T cells are effective in reducing the pool of latently infected B cells.45 This is illustrated by the effectiveness of immune surveillance against EBV in normal seropositives and by recent successes in the use of immune T cells for the treatment of EBV-positive B-cell lymphoproliferative diseases in immunosuppressed individual^.^^ We would propose that use of therapeutic agents capable of eliciting expression of the full array of EBV latency genes in cells exhibiting a type I or type I1 latency program might represent an effective treatment strategy in immunocompetent individuals. Using this approach, one might be able to change a tumor cell from an immunologically invisible target to one fully recognized by immune T cells. The observation that Burkitt's lymphoma cells can be induced to switch from a type I to a type 111 latency by treatment with 5-a~acytidine~~ suggests that this approach can be entertained.
Although the present studies are limited to one NK-like cell line, they provide initial important information on the relationship between EBV and host cells with NK phenotype. Future studies will be necessary to extend these observations to include tissue specimens representative of the full spectrum of NK cell, EBV-positive lymphoproliferative diseases.
